甲基(4-乙酰基-2-甲基苯氧基)乙酸酯 | 166953-80-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 甲基(4-乙酰基-2-甲基苯氧基)乙酸酯
• 中文别名: 2-(4-乙酰基-2-甲基苯氧基)乙酸甲酯
• 英文名称: (4-acetyl-2-methylphenoxy)acetic acid methyl ester
• 英文别名: methyl 2-(4-acetyl-2-methylphenoxy)acetate；methyl (4-acetyl-2-methyl-phenoxy)-acetate；Acetic acid, 2-(4-acetyl-2-methylphenoxy)-, methyl ester
• CAS: 166953-80-6
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: CAOUTCDDAKSUJP-UHFFFAOYSA-N

物化性质

• 沸点：
  344.9±27.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲基(4-乙酰基-2-甲基苯氧基)乙酸酯 在 甲醇 、 4-二甲氨基吡啶 、 sodium methylate 、 对甲苯磺酸 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 38.0h， 生成 methyl (4-mercapto-2-methyl-phenoxy)-acetate
  参考文献：
  名称：

  Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity

  摘要：

  We report the synthesis and biological activity of a new series of small molecule agonists of the human Peroxisome Proliferator-Activated Receptor delta (PPARdelta). Several hits were identified from our original libraries containing lipophilic carboxylic acids. Optimization of these hits by structure-guided design led to 7k (GW501516) and 71 (GW0742), which shows an EC50 Of 1.1 nM against PPARdelta with 1000-fold selectivity over the other human subtypes. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00207-5
• 作为产物：
  描述：

  邻甲酚 在 aluminum (III) chloride 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 甲基(4-乙酰基-2-甲基苯氧基)乙酸酯
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS<br/>[FR] COMPOSES ET COMPOSITIONS SERVANT DE MODULATEURS PPAR
  申请人：IRM LLC

  公开号：WO2005116000A1

  公开（公告）日：2005-12-08

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.

  这项发明提供了化合物，包括这些化合物的药物组合物，以及使用这些化合物来治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族的活性相关的疾病或紊乱的方法，特别是PPAR的活性。
• Novel compounds, their preparation and use
  申请人：Polivka Zdenék

  公开号：US20110039841A1

  公开（公告）日：2011-02-17

  Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype.

  通用公式（I）的新化合物，这些化合物作为药物组成物的用途，包含这些化合物的药物组成物以及使用这些化合物和组成物的治疗方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型。
• [EN] PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS<br/>[FR] DERIVES D'ACIDE PHENOXYACETIQUE EN TANT QU'AGONISTES DE PPAR
  申请人：NOVO NORDISK AS

  公开号：WO2005105735A1

  公开（公告）日：2005-11-10

  Novel compounds of the general formula (I), the use of these compounds as phar- maceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ suptype.

  一般式（I）的新化合物，这些化合物作为药物组成部分的用途，包括这些化合物的药物组成部分和使用这些化合物和组成部分的治疗方法。这些化合物可能在治疗和/或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中有用，特别是PPARδ亚型。
• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05556977A1

  公开（公告）日：1996-09-17

  Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

  公式I的化合物及其代谢易降解的酯和酰胺，以及其药学上可接受的盐，其中R.sup.13，M.sup.2，X.sup.1，Z.sup.1，Z.sup.1a，X.sup.2和A.sup.1具有规范中给定的含义。这些化合物可用作抑制纤维蛋白原与糖蛋白IIb/IIIa结合的抑制剂。还披露了中间体。
• Heterocyclic compouds
  申请人：Zeneca Limited

  公开号：US05753659A1

  公开（公告）日：1998-05-19

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  通式（M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过粘附分子结合到GPIIb-IIIa介导的血小板聚集参与的疾病。还披露了新的化合物。